CNS Pharmaceuticals Q3 2026 Results: Net Loss of $2.5M, Loss Narrows
CNS Pharmaceuticals reported a net loss of $10.0 million for the nine months ended September 30, 2026, while significantly strengthening its cash position to $17.2 million following a $22.5 million private placement in May 2026. The company is currently pivoting its corporate strategy toward acquiring new therapeutic assets and exploring out-licensing opportunities for its legacy glioblastoma programs.
- Key figure
- Net loss $2.5M